从胰腺癌治疗探讨进展期癌症治疗策略

Investigation of treatment strategy for advanced cancer according to treatment of pancreatic cancer

进展性或转移性胰腺癌患者预后恶劣。化疗是目前主要治疗方法。但无论是吉西他滨单用还是与其他药物联合应用,均不能有效延长患者生存期。以冷冻消融为主的综合治疗,可以延长进展性或转移性胰腺癌患者生存期。这一结果提示,采用将经皮冷冻(C)(125碘粒子植入)、肿瘤血管(微血管)介入(C)和联合免疫治疗(C)组合起来,个体化应用(P),形成"3C+P模式",可作为治疗进展性肿瘤的新策略。

The majority of pancreatic cancer diagnoses are made at the advanced stage and when metastasis has already occurred, and the 1 - and 5 -year survival rates are extremely low. Cemeitabine remains the most frequently applied treatment option, yet the most effective chemotherapeutic agents and combinations with multiple agents and/or radiotherapy only marginally improve patient survival and may even establish an environment conducive to cancer cells with stem cell - like characteristics. An alternative treatment modality, eryoablation, is a- vailable and laas been applied at our institute to patients with unresectable pancreatic cancer since 2001. In this article, we present our col- lective experience with patient outcome using cryoablation, alone or combined with other treatment modalities such as brachytherapy （125iodine seed implantation）. The overall outcomes have been encouraging, suggesting that comprehensive therapy including cryoablation may prolong the survival of patients with advanced or metastatic pancreatic cancer, and we are achieving particular success with a novel com- bination of percutaneous cryoablation, cancer microvascular intervention with 125iodine seed implantation, and combined immunotherapy （3C） applied using an individualized patient strategy （P）. The 1 - through 10 -year survival rates of 145 patients treated with the so - ca｜led ＂3C ＋ P model＂ are presented in support of this new strategy as a promising new treatment for advanced and metastatic cancer